Claudia Ramírez-Rentería
Mexican Social Security Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Claudia Ramírez-Rentería.
Experimental Diabetes Research | 2015
Aldo Ferreira-Hermosillo; Mario Molina-Ayala; Claudia Ramírez-Rentería; Guadalupe Vargas; Baldomero González; Armando Isibasi; Irma Archundia-Riveros; Victoria Mendoza
Objective. To compare the serum concentration of IL-6, IL-10, TNF, IL-8, resistin, and adiponectin in type 1 diabetic patients with and without metabolic syndrome and to determine the cut-off point of the estimated glucose disposal rate that accurately differentiated these groups. Design. We conducted a cross-sectional evaluation of all patients in our type 1 diabetes clinic from January 2012 to January 2013. Patients were considered to have metabolic syndrome when they fulfilled the joint statement criteria and were evaluated for clinical, biochemical, and immunological features. Methods. We determined serum IL-6, IL-8, IL-10, and TNF with flow cytometry and adiponectin and resistin concentrations with enzyme linked immunosorbent assay in patients with and without metabolic syndrome. We also compared estimated glucose disposal rate between groups. Results. We tested 140 patients. Forty-four percent fulfilled the metabolic syndrome criteria (n = 61), 54% had central obesity, 30% had hypertriglyceridemia, 29% had hypoalphalipoproteinemia, and 19% had hypertension. We observed that resistin concentrations were higher in patients with MS. Conclusion. We found a high prevalence of MS in Mexican patients with T1D. The increased level of resistin may be related to the increased fat mass and could be involved in the development of insulin resistance.
Diabetology & Metabolic Syndrome | 2014
Aldo Ferreira-Hermosillo; Claudia Ramírez-Rentería; Victoria Mendoza-Zubieta; Mario Molina-Ayala
BackgroundThe incidence of macrovascular complications and morbidities associated to metabolic syndrome are increasing in patients with type 1 diabetes mellitus (T1DM). The combination of T1DM with features of insulin resistance similar to that of type 2 diabetes (T2DM), sometimes called “double diabetes”, has been associated with central obesity. Since the most methods to accurately detect body fat and insulin resistance are not readily available, we propose that certain indirect indexes for detecting obesity as waist-to-height ratio, waist circumference and body mass index, may be useful when screening for metabolic syndrome in patients with T1DM.MethodsWe performed a transversal evaluation (clinical and biochemical) in all the patients of the T1DM Clinic (n = 120). We determined the presence of metabolic syndrome according to the Joint Statement Criteria by the American Heart Association/ National Heart Lung and Blood Institute and the International Diabetes Federation and the utility of certain anthropometric indexes for predicting double diabetes was evaluated.ResultsThirty seven percent of the patients were considered to have metabolic syndrome using these criteria (n = 30). These patients were significantly older (p = 0.002), have a higher glycated hemoglobin (p = 0.036), cholesterol (p < 0.012) and triglyceride concentration (p < 0.01) as well as body mass index (p = 0.004), waist circumference (p = 0.01) and waist-to-height ratio (p < 0.01) than the group without metabolic syndrome. Also their c-HDL is lower (p < 0.01). A value of 0.52 for waist-to-height ratio correctly classified the largest number of patients (68% of correctly classified) well as the waist circumference (66% of correctly classified) with an adequate specificity and sensibility. Meanwhile the most precise body mass index value only classified correctly to 61% of patients.ConclusionOur data show that waist circumference and waist-to-height ratio indexes are useful to predict the presence of metabolic syndrome in adult patients with type 1 diabetes mellitus.
Case reports in endocrinology | 2015
Mario Molina-Ayala; Claudia Ramírez-Rentería; Analleli Manguilar-León; Pedro Paúl-Gaytán; Aldo Ferreira-Hermosillo
Aldosterone-producing adrenocortical carcinomas are an extremely rare cause of hyperaldosteronism (<1%). Coexistence of different endocrine tumors warrants additional screening for multiple endocrine neoplasia syndromes, especially in young patients with large or malignant masses. We present the case of a 40-year-old man with a history of hypertension that presented with an incidental left adrenal tumor during an ultrasound performed for nephrolithiasis. Biochemical assessment showed a mildly elevated calcium (11.1 mg/dL), high parathyroid hormone, and a plasma aldosterone concentration/plasma renin activity ratio of 124.5 (normal < 30), compatible with primary hyperparathyroidism with a concomitant primary hyperaldosteronism. A Tc99m-MIBI scintigraphy showed an abnormally increased tracer uptake in the right superior parathyroid and abdominal computed tomography confirmed a left adrenal tumor of 20 cm. The patient underwent parathyroidectomy and adrenalectomy with final pathology reports of parathyroid hyperplasia and adrenal carcinoma with biochemical remission of both endocrinopathies. He was started on chemotherapy, but the patient developed a frontal cortex and an arm metastasis and finally died less than one year later.
Archive | 2018
Moisés Mercado; Claudia Ramírez-Rentería
Diabetes is recognized as one of the most common acromegaly co-morbidities with a prevalence ranging 20-53%, while over one-third of these patients have an altered lipid profile. In fact, as in the non-acromegalic population, carbohydrate and lipid metabolism abnormalities are closely linked. Long term exposure to an excess of growth hormone (GH) and Insulin-like growth factor-1 concentrations results in insulin resistance and an increased hepatic glucose production. The lipolytic effect of GH results in the mobilization of free fatty acids that further contributes to the decreased insulin sensitivity found in these patients. Some studies suggest that the presence of diabetes contributes to the increased mortality of acromegaly, although this remains controversial. Successful treatment of acromegaly usually results in significant, albeit incomplete improvements of the abnormal metabolic profile.
Endocrine | 2018
Ernesto Sosa-Eroza; Etual Espinosa; Claudia Ramírez-Rentería; Victoria Mendoza; Rocío Arreola; Moisés Mercado
Background and objectivesDopamine agonist (DA)-resistant prolactinomas are rare but they constitute a real challenge, since there are few therapeutic alternatives left for these patients.Design and settingProof-of-concept study at a tertiary care, referral center.Patients and methodsThe studied population consisted of five patients (one female and four males, mean age at diagnosis 23.5 ± 19) with macroprolactinomas with persistent hyperprolactinemia and/or tumor mass despite high doses of cabergoline (CBG) and pituitary surgery, to whom 20 mg monthly of octreotide LAR was added for 6–13 months. Response was evaluated by measuring prolactin (PRL) levels and by magnetic resonance imaging. Immunohistochemistry (IHC) for pituitary hormones, Ki-67, and somatostatin receptor subtypes 2 and 5 was (SSTR2 and 5) was available in two of the subjects.ResultsThe addition of octreotide LAR to ongoing CBG treatment had no effect on either PRL levels or tumor size in three patients. In two of the five patients, combination treatment resulted in a significant reduction in PRL concentrations (from 7643 to 200 ng/mL and from 2587 to 470 ng/mL) as well as in adenoma size (93% reduction). IHC evaluation of tumor samples from two patients (a responder and a non-responder) revealed positive immunostaining for PRL and SSTR5 but not for other pituitary hormones or for SSTR2.ConclusionsThe addition of a somatostatin analog to ongoing CBG treatment may be effective in some patients with DA-resistant macroprolactinomas, independently of the adenoma’s SSTR expression profile.
Colombia Medica | 2017
Emmanuel Valdez-Solis; Claudia Ramírez-Rentería; Aldo Ferreira-Hermosillo; Mario Molina-Ayala; Victoria Mendoza-Zubieta; Víctor Rodríguez-Pérez
Abstract Background: Gastroesophageal pathologies are common and multifactorial in patients with type 1 diabetes (T1DM). The evaluation with endoscopy and 24 h pH esophageal monitoring is expensive and not always available in all medical centers, especially in developing countries so more cost-effective algorithms for diagnosis are required. Clinical questionnaires are easy to apply but its utility for gastroesophageal reflux disease screening in patients with long standing T1DM must be analyzed. Objective: To evaluate the utility of the FSSG and Carlsson-Dent (CDQ) questionnaires to detect the frequency of gastroesophageal reflux disease in patients with T1DM. Methods: Analytic cross-sectional study, included 54 randomly selected patients from the T1DM clinic in our hospital. Before their routine evaluation, were asked to answer FSSG and CDQ questionnaires, classifying them as positive with a score >8 or >4, respectively. we associated and compared the clinical and biochemical characteristics between patients with or without gastroesophageal reflux detected through questionnaires. Results: Median age was 29 years (22-35), 67% were female (median of 16 years from diagnosis). In 39% of the patients FSSG was positive, CDQ was positive in 28%. A total of 71% of patients were taking medications to treat non-specific gastric symptoms. The concordance between questionnaires was 65% (p: <0.001). Those patients with tobacco consumption as well as those with poor glycemic control were more likely to score positive in either questionnaire. Conclusions: Patients T1DM had a high prevalence of gastroesophageal reflux disease. In those patients FSSG questionnaire detected a higher number of patients in comparison with CDQ.
Acta neuropathologica communications | 2016
Donato Iacovazzo; Richard Caswell; Benjamin Bunce; Sian Jose; Bo Yuan; Laura C. Hernández-Ramírez; Sonal Kapur; Francisca Caimari; Jane Evanson; Francesco Ferraù; Mary N. Dang; Plamena Gabrovska; Sarah Larkin; Olaf Ansorge; Celia Rodd; Mary Lee Vance; Claudia Ramírez-Rentería; Moisés Mercado; Anthony P. Goldstone; Michael Buchfelder; Christine Burren; Alper Gürlek; Pinaki Dutta; Catherine S. Choong; Tim Cheetham; Giampaolo Trivellin; Constantine A. Stratakis; Maria-Beatriz Lopes; Ashley B. Grossman; Jacqueline Trouillas
Endocrine | 2016
Claudia Ramírez-Rentería; Laura C. Hernández-Ramírez; Lesly Portocarrero-Ortiz; Guadalupe Vargas; Virgilio Melgar; Etual Espinosa; Ana Laura Espinosa-de-los-Monteros; Ernesto Sosa; Baldomero González; Sergio Zúñiga; Martina Unterländer; Joachim Burger; Karen Stals; Anne-Marie Bussell; Sian Ellard; Mary Dang; Donato Iacovazzo; Sonal Kapur; Plamena Gabrovska; Serban Radian; Federico Roncaroli; Márta Korbonits; Moisés Mercado
Revista de Endocrinología y Nutrición | 2010
Paola Jervis-Solines; Ashanti Flores-Ortega; Luis Hidalgo-Funes; Emmanuel Rivera-López; Claudia Ramírez-Rentería; Miguel Ángel Guillén-González; Moisés Mercado; Alma Vergara-López
BMC Endocrine Disorders | 2015
Victoria Mendoza-Zubieta; Gloria A Gonzalez-Villaseñor; Guadalupe Vargas-Ortega; Baldomero González; Claudia Ramírez-Rentería; Moisés Mercado; Mario Molina-Ayala; Aldo Ferreira-Hermosillo